X
[{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data for Sotatercept and MK-0616 at ACC.23\/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for MK-0616
Filters
Companies By Therapeutic Area
Details:
MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Lead Product(s):
MK-0616
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: MK-0616
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 25, 2023
Details:
MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Lead Product(s):
MK-0616
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: MK-0616
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 06, 2023
Details:
MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Lead Product(s):
MK-0616
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: MK-0616
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 21, 2023